Morton Grove Pharmaceuticals cleared to market prednisolone sodium phosphate oral solution
MORTON GROVE, ILL., October 12, 2004 -- Morton Grove
Pharmaceuticals announced that the FDA had cleared for market
Prednisolone Sodium Phosphate Oral Solution, 15mg/ 5ml. It will
treat asthma and other inflammatory conditions in children.
According to the FDA approval letter dated 17 September 2004, Morton Grove Pharmaceuticals' Prednisolone Sodium Phosphate Oral Solution, 15mg(base)/ 5ml is bioequivalent and therefore therapeutically equivalent to Orapred Oral Solution, 15mg(base)/ 5ml of Ascent Pediatrics, Inc.
Frank Stiefel, Vice President of Sales and Marketing, said, "We are very excited about this approval. Our researchers have exceeded expectations by developing a formulation that is pharmaceutically unique and convenient for patients. Not only has our product been rated therapeutically equivalent to Orapred, it offers the added benefit of not requiring refrigeration."
Source: Morton Grove Pharmaceuticals
Posted: October 2004